Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery

Nature Nanotechnology

Volumn 8, Issue 10, 2013, Pages 763-771

  Mulvey, J Justin ^a,b   Villa, Carlos H ^a,b   McDevitt, Michael R ^a   Escorcia, Freddy E ^a,b   Casey, Emily ^a   Scheinberg, David A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIUM; ALPHA PARTICLES; ASPECT RATIO; CELLS; CONTROLLED DRUG DELIVERY; DISEASES; GAMMA RAYS; MAMMALS; MONOCLONAL ANTIBODIES; NANOTUBES; OLIGONUCLEOTIDES; RADIOISOTOPES; SELF ASSEMBLY; TARGETED DRUG DELIVERY; TUMORS; YARN;

BINDING PROCESS; HIGH ASPECT RATIO; HIGH SPECIFIC ACTIVITIES; IMAGING AGENT; OLIGONUCLEOTIDE SEQUENCES; SINGLE-WALLED CARBON NANOTUBE (SWNTS); SMALL MOLECULES; TWO-STEP APPROACH;

SINGLE-WALLED CARBON NANOTUBES (SWCN);

ANTIBODY; LINTUZUMAB; RITUXIMAB; SINGLE WALLED NANOTUBE;

ALPHA RADIATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GAMMA RADIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYBRIDIZATION; ISOTOPE LABELING; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; MICE; MORPHOLINOS; NANOTUBES, CARBON; NEOPLASMS; RADIOISOTOPES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885481781     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2013.190     Document Type: Article

References (45)

1. Scheinberg, D. A., Villa, C. H., Escorcia, F. E. & McDevitt, M. R. Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Rev. Clin. Oncol. 7, 266-276 (2010)
2. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Rev. Drug Discov. 7, 771-782 (2008)
3. Kostarelos, K., Bianco, A. & Prato, M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nature Nanotech. 4, 627-633 (2009)
4. Liu, Z. et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68, 6652-6660 (2008)
5. Liu, Z. et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nature Nanotech. 2, 47-52 (2007)
6. Villa, C. H. et al. Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumour-associated antigens. ACS Nano. 5, 5300-5311 (2011)
7. Villa, C. H. et al. Synthesis and biodistribution of oligonucleotidefunctionalized, tumour-targetable carbon nanotubes. Nano Lett. 8, 4221-4228 (2008)
8. McDevitt, M. R. et al. PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS ONE 2, e907 (2007)
9. McDevitt, M. R. et al. Tumour targeting with antibody-functionalized, radiolabeled carbon nanotubes. J. Nucl. Med. 48, 1180-1189 (2007)
10. Ruggiero, A. et al. Imaging and treating tumour vasculature with targeted radiolabeled carbon nanotubes. Int. J. Nanomed. 5, 783-802 (2010)
11. Singh, R. et al. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc. Natl Acad. Sci. USA 103, 3357-3362 (2006)
12. Liu, Z. et al. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc. Natl Acad. Sci. USA 105, 1410-1415 (2008)
13. Mutlu, G. K. M. et al. Biocompatible nanoscale dispersion of single-walled carbon nanotubes minimizes in vivo pulmonary toxicity. Nano Lett. 10, 1664-1670 (2010).
14. Ruggiero, A. et al. Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl Acad. Sci. USA 107, 12369-12374 (2010)
15. Lacerda, L. et al. Carbon-nanotube shape and individualization critical for renal excretion. Small 4, 1130-1132 (2008)
16. Kostarelos, K. Carbon nanotubes: fibrillar pharmacology. Nature Mater. 9, 793-795 (2010)
17. Goldenberg, D., Sharkey, R., Paganelli, G. & Barbet, J. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 10, 823-834 (2006)
18. Green, D. J. et al. Pretargeted radioimmunotherapy for B-cell lymphomas. Clin. Cancer Res. 13, 5598s-5603s (2007)
19. Sharkey, R. M. et al. Improved therapy of non-Hodgkin?s lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 19, 1064-1069 (2005)
20. Liu, G. et al. Successful radiotherapy of tumour in pretargeted mice by 188Reradiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue. Clin. Cancer. Res. 12, 4958-4964 (2006)
21. Rossin, R. et al. In vivo chemistry for pretargeted tumour imaging in live mice. Angew. Chem. Int. Ed. 49, 3375-3378 (2010)
22. Park, J-H. et al. Cooperative nanomaterial system to sensitize, target, and treat tumours. Proc. Natl Acad. Sci. USA 107, 981-986 (2010)
23. Perrault, S. D. & Chan, W. C. W. In vivo assembly of nanoparticle components to improve targeted cancer imaging. Proc. Natl Acad. Sci. USA 107, 11194-11199 (2010)
24. Liu, G. et al. Adding a clearing agent to pretargeting does not lower the tumour accumulation of the effector as predicted. Cancer Biother. Radio. 25, 757-762 (2010)
25. Alvarez-Diez, T. M., Polihronis, J. & Reilly, R. M. Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin. Nucl. Med. and Biol. 23, 459-466 (1996)
26. He, J. et al. Affinity enhancement pretargeting: synthesis and testing of a (99m)Tc-labeled bivalent MORF. Mol. Pharmacol. 2, 1118-1124 (2010)
27. Staii, C., Johnson, A. T., Chen, M. & Gelperin, A. DNA-decorated carbon nanotubes for chemical sensing. Nano Lett. 5, 1774-1778 (2005)
28. Liu, G. et al. Tumour pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. J. Nucl. Med. 43, 384-391 (2002)
29. Moulton, H. M. et al. Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. Ann. NY Acad. Sci. 1175, 55-60 (2009)
30. Park, S. Y. et al. DNA-programmable nanoparticle crystallization. Nature 451, 553-556 (2008)
31. Hnatowic, D. J. & Nakamura, K. The influence of chemical structure of DNA and other oligomer radiopharmaceuticals on tumour delivery. Curr. Opin. Mol. Ther. 8, 136-143 (2006)
32. Georgakilas, V. et al. Organic functionalization of carbon nanotubes. J. Am. Chem. Soc. 124, 760-761 (2002)
33. Georgakilas, V. et al. Amino acid functionalisation of water soluble carbon nanotubes. Chem Commun. 3050-3051 (2002)
34. McDevitt, M. R. et al. Tumour therapy with targeted atomic nanogenerators. Science 294, 1537-1540 (2001)
35. He, J. et al. An improved method for covalently conjugating morpholino oligomers to antitumour antibodies. Bioconjug. Chem. 18, 983-988 (2007)
36. Ackerman, M. E. et al. A33 antigen displays persistent surface expression. Cancer Immunol. Immunother. 57, 1017-1027 (2008)
37. Welt, S. et al. Phase I study of anticolon cancer humanized antibody A33. Clin. Cancer Res. 9, 1338-1346 (2003)
38. Golay, J. et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95, 3900-3908 (2000)
39. Miederer, M., Scheinberg, D. & McDevitt, M. Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv. Drug Deliv. Rev. 60, 1371-1382 (2008)
40. Song, H. et al. Radioimmunotherapy of breast cancer metastases with alphaparticle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 69, 8941-8948 (2009)
41. Miederer, M. et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J. Nucl. Med. 45, 129-137 (2004)
42. Liu, G. & Hnatowich, D. J. A semiempirical model of tumour pretargeting. Bioconjug. Chem. 19, 2095-2104 (2008)
43. Vegt, E. et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J. Nucl. Med. 51, 1049-1058 (2010)
44. Kaiser, E., Colescott, R. L., Bossinger, C. D. & Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34, 595-598 (1970)
45. Liu, G. et al. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur. J. Nucl. Med. Mol. I 34, 237-246 (2007)